Cargando…

Initiation of triple therapy maintenance treatment among patients with COPD in the US

BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 agonists, and inhaled corticosteroids) for patients with only the most severe COPD. Data on the proportion of COPD patients on trip...

Descripción completa

Detalles Bibliográficos
Autores principales: Simeone, Jason C, Luthra, Rakesh, Kaila, Shuchita, Pan, Xiaoyun, Bhagnani, Tarun D, Liu, Jieruo, Wilcox, Teresa K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191839/
https://www.ncbi.nlm.nih.gov/pubmed/28053518
http://dx.doi.org/10.2147/COPD.S122013
_version_ 1782487694790623232
author Simeone, Jason C
Luthra, Rakesh
Kaila, Shuchita
Pan, Xiaoyun
Bhagnani, Tarun D
Liu, Jieruo
Wilcox, Teresa K
author_facet Simeone, Jason C
Luthra, Rakesh
Kaila, Shuchita
Pan, Xiaoyun
Bhagnani, Tarun D
Liu, Jieruo
Wilcox, Teresa K
author_sort Simeone, Jason C
collection PubMed
description BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 agonists, and inhaled corticosteroids) for patients with only the most severe COPD. Data on the proportion of COPD patients on triple therapy and their characteristics are sparse and dated. Objective 1 of this study was to estimate the proportion of all, and all treated, COPD patients receiving triple therapy. Objective 2 was to characterize those on triple therapy and assess the concordance of triple therapy use with GOLD guidelines. PATIENTS AND METHODS: This retrospective study used claims from the IMS PharMetrics Plus database from 2009 to 2013. Cohort 1 was selected to assess Objective 1 only; descriptive analyses were conducted in Cohort 2 to answer Objective 2. A validated claims-based algorithm and severity and frequency of exacerbations were used as proxies for COPD severity. RESULTS: Of all 199,678 patients with COPD in Cohort 1, 7.5% received triple therapy after diagnosis, and 25.5% of all treated patients received triple therapy. In Cohort 2, 30,493 COPD patients (mean age =64.7 years) who initiated triple therapy were identified. Using the claims-based algorithm, 34.5% of Cohort 2 patients were classified as having mild disease (GOLD 1), 40.8% moderate (GOLD 2), 22.5% severe (GOLD 3), and 2.3% very severe (GOLD 4). Using exacerbation severity and frequency, 60.6% of patients were classified as GOLD 1/2 and 39.4% as GOLD 3/4. CONCLUSION: In this large US claims database study, one-quarter of all treated COPD patients received triple therapy. Although triple therapy is recommended for the most severe COPD patients, spirometry is infrequently assessed, and a majority of the patients who receive triple therapy may have only mild/moderate disease. Any potential overprescribing of triple therapy may lead to unnecessary costs to the patient and health care system.
format Online
Article
Text
id pubmed-5191839
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-51918392017-01-04 Initiation of triple therapy maintenance treatment among patients with COPD in the US Simeone, Jason C Luthra, Rakesh Kaila, Shuchita Pan, Xiaoyun Bhagnani, Tarun D Liu, Jieruo Wilcox, Teresa K Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends triple therapy (long-acting muscarinic receptor antagonists, long-acting beta-2 agonists, and inhaled corticosteroids) for patients with only the most severe COPD. Data on the proportion of COPD patients on triple therapy and their characteristics are sparse and dated. Objective 1 of this study was to estimate the proportion of all, and all treated, COPD patients receiving triple therapy. Objective 2 was to characterize those on triple therapy and assess the concordance of triple therapy use with GOLD guidelines. PATIENTS AND METHODS: This retrospective study used claims from the IMS PharMetrics Plus database from 2009 to 2013. Cohort 1 was selected to assess Objective 1 only; descriptive analyses were conducted in Cohort 2 to answer Objective 2. A validated claims-based algorithm and severity and frequency of exacerbations were used as proxies for COPD severity. RESULTS: Of all 199,678 patients with COPD in Cohort 1, 7.5% received triple therapy after diagnosis, and 25.5% of all treated patients received triple therapy. In Cohort 2, 30,493 COPD patients (mean age =64.7 years) who initiated triple therapy were identified. Using the claims-based algorithm, 34.5% of Cohort 2 patients were classified as having mild disease (GOLD 1), 40.8% moderate (GOLD 2), 22.5% severe (GOLD 3), and 2.3% very severe (GOLD 4). Using exacerbation severity and frequency, 60.6% of patients were classified as GOLD 1/2 and 39.4% as GOLD 3/4. CONCLUSION: In this large US claims database study, one-quarter of all treated COPD patients received triple therapy. Although triple therapy is recommended for the most severe COPD patients, spirometry is infrequently assessed, and a majority of the patients who receive triple therapy may have only mild/moderate disease. Any potential overprescribing of triple therapy may lead to unnecessary costs to the patient and health care system. Dove Medical Press 2016-12-22 /pmc/articles/PMC5191839/ /pubmed/28053518 http://dx.doi.org/10.2147/COPD.S122013 Text en © 2017 Simeone et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Simeone, Jason C
Luthra, Rakesh
Kaila, Shuchita
Pan, Xiaoyun
Bhagnani, Tarun D
Liu, Jieruo
Wilcox, Teresa K
Initiation of triple therapy maintenance treatment among patients with COPD in the US
title Initiation of triple therapy maintenance treatment among patients with COPD in the US
title_full Initiation of triple therapy maintenance treatment among patients with COPD in the US
title_fullStr Initiation of triple therapy maintenance treatment among patients with COPD in the US
title_full_unstemmed Initiation of triple therapy maintenance treatment among patients with COPD in the US
title_short Initiation of triple therapy maintenance treatment among patients with COPD in the US
title_sort initiation of triple therapy maintenance treatment among patients with copd in the us
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191839/
https://www.ncbi.nlm.nih.gov/pubmed/28053518
http://dx.doi.org/10.2147/COPD.S122013
work_keys_str_mv AT simeonejasonc initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT luthrarakesh initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT kailashuchita initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT panxiaoyun initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT bhagnanitarund initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT liujieruo initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus
AT wilcoxteresak initiationoftripletherapymaintenancetreatmentamongpatientswithcopdintheus